post-quantum-secure-pharmacovigilance

name	post-quantum-secure-pharmacovigilance
description	NIST-standard PQC migration (ML-KEM + ML-DSA) for pharmacovigilance and healthcare data systems. Use when designing post-quantum security for adverse event reporting, clinical observation systems, or any healthcare pipeline handling sensitive patient data that needs quantum-resistant cryptography.
metadata	{"arxiv_id":"2606.09412","published":"2026-06-09","authors":"Saee Desai, Tom Shimoni, Eddie Cameron, David Akamine, Aniketh Chunduri","tags":["post-quantum-cryptography","pharmacovigilance","ML-KEM","ML-DSA","healthcare-security"]}

Post-Quantum Secure Pharmacovigilance

Core Framework

This paper presents the first practical PQC migration framework for pharmacovigilance systems — critical infrastructure handling adverse drug reaction reports, clinical trial data, and patient safety information.

Key Components

1. ML-KEM (CRYSTALS-Kyber): Post-quantum key encapsulation for encrypting pharmacovigilance data in transit. Replaces RSA/ECDH in the E2E pipeline.
2. ML-DSA (CRYSTALS-Dilithium): Post-quantum digital signatures for authenticating adverse event reports and ensuring non-repudiation of submissions.
3. Hybrid TLS Migration: Gradual migration strategy combining classical + PQC algorithms during transition period, ensuring backward compatibility with legacy healthcare systems.

Security Properties

• Confidentiality: ML-KEM-768 provides NIST Level 3 security (equivalent to AES-256)
• Integrity: ML-DSA-65 provides authenticated report submission
• Harvest-now-decrypt-later protection: Even if adversaries harvest encrypted pharmacovigilance data today, they cannot decrypt it with future quantum computers

Activation

• 药品安全, pharmacovigilance security, post-quantum healthcare
• ML-KEM, ML-DSA, CRYSTALS migration
• 抗量子药物监测, quantum-resistant adverse event system
• healthcare data encryption, PQC migration

Implementation Patterns

Pattern 1: Secure Adverse Event Submission Pipeline

Reporter → ML-DSA signature verification → ML-KEM encrypted channel → Central PV Database

Pattern 2: Hybrid TLS for Healthcare Interoperability

During migration, support both:

• Classical TLS 1.3 (ECDHE + AES-256-GCM)
• Hybrid TLS 1.3 (X25519 + ML-KEM-768, AES-256-GCM)

Pitfalls

• Regulatory compliance: FDA/EMA pharmacovigilance systems have strict validation requirements — PQC migration must not alter data integrity guarantees
• Performance overhead: ML-KEM key exchange adds ~2-3ms latency; ML-DSA signature verification adds ~1ms — acceptable for most PV workflows but test with high-volume systems
• Key size: ML-KEM-768 ciphertexts are 1088 bytes (vs 32 bytes for X25519) — may impact bandwidth-constrained IoMT devices

Research Trend: Quantum's Dual Role in Healthcare (2026-06-11)

An important cross-domain pattern emerged from medicine + quantum research:

Quantum Role	Example Papers	Skills
Accelerate medical AI	HQNN blood cell classification (2605.23324), Hybrid FBPINN for scientific computing (2606.01110)	hqnn-blood-cell-classification, hybrid-quantum-fbpinn
Protect medical infrastructure	PQC pharmacovigilance (2606.09412), Quantum tunneling PUF for IoMT (2605.22113)	post-quantum-secure-pharmacovigilance, qt-puf-quantum-tunneling-iomt

When researching quantum + medicine, always check for BOTH roles — the literature increasingly covers quantum as both enabler and threat-mitigator for healthcare systems.

References

• arXiv: 2606.09412 - "Towards Post-Quantum Secure Pharmacovigilance with ML-KEM and ML-DSA"
• NIST FIPS 203 (ML-KEM) and FIPS 204 (ML-DSA)